Bristol-Myers Squibb came through in Q2 on both the sales and earnings fronts and raised guidance once again. But it wasn’t Opdivo and the usual suspects…

It’s a silver-lining quarter for AstraZeneca. Second-quarter sales slid--but not as far as market watchers expected--and new cancer meds, diabetes drugs and…

As England's cost watchdogs were weighing Gilead’s evidence and pricing for its hep C drugs, the country’s National Health Service was maneuvering to…

With billions in sales under biosimilar threat and facing investor pressure to make M&A moves, Amgen on Wednesday posted revenue and earnings beats for the…

GlaxoSmithKline CEO Andrew Witty is sitting pretty. For the second straight quarter, his much-maligned growth strategy has come through for the drugmaker,…

Bayer’s pharma lineup churned out growth for yet another quarter, racking up a 5.5% sales hike to €4.1 billion as the blood thinner Xarelto and vision med…

GlaxoSmithKline is not planning to exit the U.K. just because the U.K. is exiting the European Union. As if to emphasize its commitment, the drugmaker today…

Eli Lilly & Co. CEO John Lechleiter is moving on. The outspoken CEO--who presided over a tumultuous period at Lilly, always promising a turnaround--will…

The Philadelphia host committee of the Democratic National Convention has hired a healthcare agency to manage its social media and digital this week--and …